Abstract
As has been noted in the previous papers on individual clinical trials and the latest overview update [1] (reprinted in part in this volume), systemic adjuvant therapy has resulted in a significant and long-lasting reduction in mortality due to early breast cancer. However, it is also apparent from these analyses that many patients develop metastatic disease and die of breast cancer despite having received standard adjuvant therapeutic regimens. In order to achieve further improvement in survival with systemic adjuvant therapy, several hurdles must be surmounted, including (a) enhanced ability to identify patients who are unlikely to respond to current treatments and (b) development of more effective therapies. This paper focuses on the latter issue and specifically the use of high-dose cytotoxic chemotherapy as an approach to improving systemic adjuvant therapy.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Early Breast Cancer Trialists’ Collaborative Group (1992) Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy. Lancet 339: 1–15, 71–84
Levine MN, Browman GP, Gent M et al. (1991) When is a prognostic factor useful? A guide for the perplexed. J Clin Oncol 9:348–356
Callahan R, Campbell G (1989) Mutations in human breast cancer: an overview. J Natl Cancer Inst 81:1780–1786
Bonadonna G, Valagussa P, Zambetti N et al. (1987) Milan adjuvant trials for stage I-II breast cancer. In: Salmon S (ed) Adjuvant therapy of cancer V. Grune and Stratton, New York, pp 211–221
Buzzoni R, Bonnadonna G, Valagussa P, Zambetti M (1991) Adjuvant chemotherapy with doxorubicin plus cyclophosphamide, methotrexate and fluorouracil in the treatment of resectable breast cancer with more than three positive axillary nodes, J Clin Oncol 9:2134–2140
Teicher BA, Cucchi CA, Lee JB et al. (1986) Alkylating agents: in vitro studies of cross-resistance patterns in human cell lines. Cancer Res 46:4379–4383
Hryniuk W, Levine MN (1986) Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer. J Clin Oncol 4:1162–1170
Tannock IF, Boyd NF, DeBoer G et al. (1988) A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast cancer. J Clin Oncol 6:1377–1387
Hortobagyi GN, Buzdar AU, Bodey GP et al. (1987) High-dose induction chemotherapy of metastatic breast cancer in protected environment: a prospective randomized study. J Clin Oncol 5:178–184
Hortobagyi GN, Hryniuk WH, Frye D et al. (1989) Dose-intensity (DI) analysis of high-dose (HD) chemotherapy for metastatic breast cancer (MBC). Proc Am Assoc Cancer Res 30:252
Abeloff MD, Beveridge RE, Donehower RC et al. (1990) Sixteen-week dose- intense chemotherapy in the adjuvant treatment of breast cancer. J Natl Cancer Inst 82:1220–1221
Armitage JO (1990) Bone marrow transplantation in the treatment of lymphoma. Curr Opin Oncol 2:843–848
Henderson IC (1991) Window of opportunity. J Natl Cancer Inst 83:894–896
Kennedy MK, Beveridge RA, Rowley SD et al. (1991) High dose chemotherapy with reinfusion of purged autologous bone marrow following dose-intense induction as initial therapy for metastatic breast cancer. J Natl Cancer Inst 83:920–925
Peters WP (1991) High-dose chemotherapy and autologous bone marrow support for breast cancer. In: Devita VT Jr, Heilman S, Rosenberg SA (eds) Important advances in oncology 1991. Lippincott, Philadelphia, pp 135–150
Tajima T, Tokuda Y, Kubota M et al. (1990) Adjuvant chemotherapy with reinfusion of purged autologous bone marrow following dose-intense induction as initial therapy for metastatic breast cancer. Proc Am Soc Clin Oncol 9:31
Fowble B, Gray R, Gilchrist K et al. (1988) Identification of a subgroup of patients with breast cancer and histologically positive axillary nodes receiving adjuvant chemotherapy who may benefit from postoperative radiotherapy. J Clin Oncol 6:1107–1117
Geller RB, Esa AH, Beschorner WE et al. (1989) Successful in vitro graft versus tumor effect against an Ia bearing tumor using cyclosporin-induced syngeneic graft versus host disease in the rat. Blood 74:1165–1171
Eder JP (1989) Effect of novobiocin on the antitumor activity and tumor cell and bone marrow survivors of three alkylating agents. Cancer Res 49:595–598
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1993 Springer-Verlag Berlin · Heidelberg
About this paper
Cite this paper
Abeloff, M.D. (1993). High-Dose Adjuvant Chemotherapy for High-Risk Breast Cancer. In: Senn, HJ., Gelber, R.D., Goldhirsch, A., Thürlimann, B. (eds) Adjuvant Therapy of Breast Cancer IV. Recent Results in Cancer Research, vol 127. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-84745-5_25
Download citation
DOI: https://doi.org/10.1007/978-3-642-84745-5_25
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-84747-9
Online ISBN: 978-3-642-84745-5
eBook Packages: Springer Book Archive